Applicants: David Stern and Ann-Marie Schmidt

Serial No.: 08/905,709 Filing Date: August 5, 1997

Page 2

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

- Claim 1 (currently amended) A method of inhibiting atherosclerosis in a subject suffering from hyperlipidemia which comprises administering to the subject a polypeptide comprising the [[V-domain of sRAGE]] extracellular domain of soluble receptor for advanced glycation endproduct (sRAGE) or a derivative thereof capable of inhibiting an interaction between [[AGE and RAGE]] amyloid- β peptide and receptor for advanced glycation endproduct (RAGE) in an effective to inhibit atherosclerosis in the subject.
- Claim 2 (original) The method of claim 1, wherein the subject is a mammal.
- Claim 3 (original) The method of claim 2, wherein the mammal is a human.
- Claim 4 (original) The method of claim 1, wherein the subject is a diabetic subject.

Claim 5-7 (canceled)

Claim 8 (original) The method of claim 1, wherein the subject has

Applicants: David Stern and Ann-Marie Schmidt

Serial No.: 08/905,709
Filing Date: August 5, 1997

Page 3

a glucose metabolism disorder.

Claim 9 (original) The method of claim 1, wherein the subject is an obese subject.

Claim 10-14 (canceled)

- Claim 15 (original) The method of claim 1, further comprising administering to the subject a pharmaceutically acceptable carrier during the administration of the polypeptide.
- Claim 16 (previously presented) The method of claim 1, wherein the administering is effected by intralesional, intraperitoneal, intramuscular or intravenous injection, infusion, liposome-mediated delivery, or topical, nasal, oral, ocular or otic delivery
- Claim 17 (original) The method of claim 1, wherein the polypeptide is administered daily.
- Claim 18 (original) The method of claim 1, wherein the effective amount of the polypeptide comprises from about 0.000001 mg/kg body weight to about 100 mg/kg body weight.

Claim 19-35 (canceled)

Claim 36 (previously presented) The method of claim 1, wherein the hyperlipidemia is hypercholesterolemia.

Applicants: David Stern and Ann-Marie Schmidt

Serial No.: 08/905,709
Filing Date: August 5, 1997

Page 4

Claim 37 (previously presented) The method of claim 1, wherein the hyperlipidemia is hypertriglyceridemia.

Claim 38-39 (canceled)

- Claim 40 (withdrawn) The method of claim 1, wherein the agent is an antibody or portion thereof capable of specifically binding to RAGE.
- Claim 41 (withdrawn) The method of claim 40, wherein the antibody is a monoclonal antibody.
- Claim 42 (withdrawn) The method of claim 40, wherein the antibody is a polyclonal antibody.
- Claim 43 (withdrawn) The method of claim 40, wherein the portion of the antibody is a complementarity determining region.
- Claim 44 (withdrawn) The method of claim 40, wherein the portion of the antibody is a variable region.
- Claim 45 (withdrawn) The method of claim 40, wherein the portion of the antibody is an Fab portion.
- Claim 46 (previously presented) The method of claim 1, wherein the polypeptide is admixed with a pharmaceutically acceptable carrier.